Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Assets (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Non-Current Assets for 7 consecutive years, with $212.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 5.84% to $212.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $860.0 million, a 6.66% decrease, with the full-year FY2025 number at $212.5 million, down 5.84% from a year prior.
  • Non-Current Assets was $212.5 million for Q4 2025 at Beam Therapeutics, roughly flat from $212.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $259.1 million in Q2 2023 to a low of $178.7 million in Q1 2021.
  • A 5-year average of $227.1 million and a median of $225.8 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 230.16% in 2021, then decreased 10.52% in 2024.
  • Beam Therapeutics' Non-Current Assets stood at $201.4 million in 2021, then grew by 23.52% to $248.8 million in 2022, then decreased by 0.06% to $248.7 million in 2023, then fell by 9.25% to $225.7 million in 2024, then fell by 5.84% to $212.5 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Non-Current Assets are $212.5 million (Q4 2025), $212.5 million (Q3 2025), and $215.7 million (Q2 2025).